Payment overview · 2025
General Payments
$1,642.46
67 reported records · 15 companies
Healthcare provider profile · identity verified
Gail G. Bryant, MD
Allopathic & Osteopathic Physicians|Family Medicine · ARLINGTON HTS, IL · NPI 1447202064
Verified facts
What the public records show
CMS Open Payments records show Gail G. Bryant, MD received $1,642.46 in general payments during 2025 across 67 reported records.
Corcept Therapeutics accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $357.14 | 21.7% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $245.54 | 14.9% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $242.27 | 14.8% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $179.01 | 10.9% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $137.11 | 8.3% | 6 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $125.30 | 7.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.72 | 6.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.61 | 4.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.38 | 2.7% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.98 | 1.5% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $22.52 | 1.4% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $21.30 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.01 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.38 | 1.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.19 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,642.46 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $357.14 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $242.27 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $190.97 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $144.78 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $137.11 | 6 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $125.30 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.73 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $78.61 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.23 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 41 |
| Montelukast Sodium | Montelukast Sodium | 115 | 35 |
| Prednisone | Prednisone | 114 | 61 |
| Lisinopril | Lisinopril | 111 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 100 | 31 |
| Furosemide | Furosemide | 100 | 30 |
| Metformin Hcl | Metformin Hcl | 73 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 22 |
| Gabapentin | Gabapentin | 66 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 20 |
| Losartan Potassium | Losartan Potassium | 65 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 58 | 17 |
| Omeprazole | Omeprazole | 57 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 20 |
| Alprazolam | Alprazolam | 54 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 17 |
| Simvastatin | Simvastatin | 51 | 16 |
| Tramadol Hcl | Tramadol Hcl | 50 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 14 |
| Sertraline Hcl | Sertraline Hcl | 48 | 12 |
| Allopurinol | Allopurinol | 45 | 11 |
| Clarithromycin | Clarithromycin | 43 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 18 |
| Azithromycin | Azithromycin | 36 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 14 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 13 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Alosetron Hcl | Alosetron Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 12 |
| Levofloxacin | Levofloxacin | 20 | 15 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Baclofen | Baclofen | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Glipizide | Glipizide | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,642.46 · 67 records | Corcept Therapeutics | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, COMIRNATY, CONTRAVE, Da Vinci Surgical System, ELIQUIS, Fibroscan, Kerendia, Korlym, NP Thyroid 60, ONZETRA XSAIL, OTEZLA, Ozempic, PREVNAR 20, Qelbree, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error